Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALBO NASDAQ:EOLS NASDAQ:LXRX NASDAQ:NERV NASDAQ:SPPI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALBOAlbireo Pharma$44.15$44.17$16.02▼$45.23$913.91M1.03704,539 shs1.24 million shsEOLSEvolus$6.74-1.2%$6.78$5.71▼$17.44$435.62M1.041.07 million shs97,054 shsLXRXLexicon Pharmaceuticals$1.42+1.8%$1.27$0.28▼$2.08$514.21M1.237.25 million shs363,072 shsNERVMinerva Neurosciences$4.96-7.9%$2.43$1.15▼$12.46N/A-0.3937,900 shs570,985 shsSPPISpectrum Pharmaceuticals$1.03$1.01$0.32▼$1.57$211.41M2.151.93 million shsN/AAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALBOAlbireo Pharma0.00%0.00%0.00%0.00%0.00%EOLSEvolus+0.44%+3.18%+8.08%-29.33%-57.48%LXRXLexicon Pharmaceuticals-3.47%-9.15%+19.83%+23.01%-28.35%NERVMinerva Neurosciences-16.07%+114.34%+158.65%+147.93%+116.94%SPPISpectrum Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALBOAlbireo Pharma$44.15$44.17$16.02▼$45.23$913.91M1.03704,539 shs1.24 million shsEOLSEvolus$6.74-1.2%$6.78$5.71▼$17.44$435.62M1.041.07 million shs97,054 shsLXRXLexicon Pharmaceuticals$1.42+1.8%$1.27$0.28▼$2.08$514.21M1.237.25 million shs363,072 shsNERVMinerva Neurosciences$4.96-7.9%$2.43$1.15▼$12.46N/A-0.3937,900 shs570,985 shsSPPISpectrum Pharmaceuticals$1.03$1.01$0.32▼$1.57$211.41M2.151.93 million shsN/AAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALBOAlbireo Pharma0.00%0.00%0.00%0.00%0.00%EOLSEvolus+0.44%+3.18%+8.08%-29.33%-57.48%LXRXLexicon Pharmaceuticals-3.47%-9.15%+19.83%+23.01%-28.35%NERVMinerva Neurosciences-16.07%+114.34%+158.65%+147.93%+116.94%SPPISpectrum Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALBOAlbireo Pharma 0.00N/AN/AN/AEOLSEvolus 2.40Hold$21.25215.52% UpsideLXRXLexicon Pharmaceuticals 2.29Hold$3.23127.92% UpsideNERVMinerva Neurosciences 1.50Reduce$5.000.91% UpsideSPPISpectrum Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SPPI, LXRX, NERV, ALBO, and EOLS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/14/2025EOLSEvolusWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025LXRXLexicon PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025NERVMinerva NeurosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)9/27/2025EOLSEvolusWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025LXRXLexicon PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025NERVMinerva NeurosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)9/8/2025EOLSEvolusBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$18.009/2/2025LXRXLexicon PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$4.008/7/2025LXRXLexicon PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$1.20 ➝ $1.908/6/2025EOLSEvolusBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$21.00 ➝ $18.008/6/2025EOLSEvolusHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$27.00 ➝ $20.00(Data available from 10/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALBOAlbireo Pharma$40.58M22.52N/AN/A$9.11 per share4.85EOLSEvolus$266.27M1.64N/AN/A$0.09 per share74.83LXRXLexicon Pharmaceuticals$31.08M16.54N/AN/A$0.40 per share3.54NERVMinerva NeurosciencesN/AN/A$0.16 per share30.67($3.67) per shareN/ASPPISpectrum Pharmaceuticals$10.11M20.91N/AN/A$0.15 per share6.87Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALBOAlbireo Pharma-$34.03M-$6.72N/AN/AN/A-228.51%-97.13%-46.89%N/AEOLSEvolus-$50.42M-$0.98N/AN/AN/A-22.31%-759.04%-24.63%11/5/2025 (Estimated)LXRXLexicon Pharmaceuticals-$200.40M-$0.33N/AN/AN/A-206.43%-83.63%-42.22%11/11/2025 (Estimated)NERVMinerva Neurosciences$1.44M$1.483.35N/AN/AN/A-41.35%31.37%11/4/2025 (Estimated)SPPISpectrum Pharmaceuticals-$75.40M-$0.36N/A14.71N/AN/A-218.44%-66.16%N/ALatest SPPI, LXRX, NERV, ALBO, and EOLS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025LXRXLexicon Pharmaceuticals-$0.07N/AN/AN/A$5.81 millionN/A11/5/2025Q3 2025EOLSEvolus-$0.14N/AN/AN/A$67.75 millionN/A11/4/2025Q3 2025NERVMinerva Neurosciences-$0.35N/AN/AN/AN/AN/A8/14/2025Q2 2025NERVMinerva Neurosciences-$0.95-$0.43+$0.52-$0.43N/AN/A8/6/2025Q2 2025LXRXLexicon Pharmaceuticals-$0.08$0.01+$0.09$0.01$4.87 million$28.87 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALBOAlbireo PharmaN/AN/AN/AN/AN/AEOLSEvolusN/AN/AN/AN/AN/ALXRXLexicon PharmaceuticalsN/AN/AN/AN/AN/ANERVMinerva NeurosciencesN/AN/AN/AN/AN/ASPPISpectrum PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALBOAlbireo PharmaN/A6.326.23EOLSEvolusN/A2.271.86LXRXLexicon Pharmaceuticals0.434.164.16NERVMinerva NeurosciencesN/A6.156.15SPPISpectrum PharmaceuticalsN/A2.712.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALBOAlbireo Pharma94.25%EOLSEvolus90.69%LXRXLexicon Pharmaceuticals74.70%NERVMinerva Neurosciences34.56%SPPISpectrum Pharmaceuticals21.67%Insider OwnershipCompanyInsider OwnershipALBOAlbireo Pharma6.90%EOLSEvolus5.90%LXRXLexicon Pharmaceuticals13.90%NERVMinerva Neurosciences8.60%SPPISpectrum Pharmaceuticals2.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALBOAlbireo Pharma13020.70 million19.27 millionOptionableEOLSEvolus17064.68 million60.87 millionOptionableLXRXLexicon Pharmaceuticals140363.40 million312.89 millionOptionableNERVMinerva Neurosciences9N/AN/ANot OptionableSPPISpectrum Pharmaceuticals86205.25 million199.70 millionOptionableSPPI, LXRX, NERV, ALBO, and EOLS HeadlinesRecent News About These CompaniesSPECTRUM FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Class Action Lawsuit Filed Against Spectrum Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm Before September 24thSeptember 23, 2025 | globenewswire.comCLASS ACTION DEADLINE APPROACHING: Berger Montague Advises Spectrum Pharmaceuticals (NASDAQ: SPPI) Investors to Inquire About a Securities Fraud Class Action by September 24, 2025September 23, 2025 | prnewswire.comSPPI FINAL DEADLINE: ROSEN, TOP RANKED INVESTOR RIGHTS COUNSEL, Encourages Spectrum ...September 22, 2025 | bakersfield.comBSPPI FINAL DEADLINE: ROSEN, TOP RANKED INVESTOR RIGHTS COUNSEL, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important September 24 Deadline in Securities Class Action – SPPISeptember 22, 2025 | globenewswire.comSPPI Investors Have Opportunity to Lead Spectrum Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law FirmSeptember 22, 2025 | prnewswire.comSPPI Deadline: Rosen Law Firm Urges Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their RightsSeptember 21, 2025 | businesswire.comSPPI Deadline: SPPI Investors with Losses in Excess of $100K Have Opportunity to Lead Spectrum Pharmaceuticals, Inc. Securities Fraud LawsuitSeptember 20, 2025 | prnewswire.comSPPI DEADLINE NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Spectrum Pharmaceuticals,September 19, 2025 | reflector.comRSPPI FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important September 24 Deadline in Securities Class ...September 19, 2025 | cantechletter.comCSPPI DEADLINE NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important September 24 Deadline in Securities Class Action – SPPISeptember 19, 2025 | globenewswire.comSPECTRUM DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors of the Class Action Lawsuit Filed Against Spectrum Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm Before September 24thSeptember 19, 2025 | globenewswire.comSpectrum Pharmaceuticals (SPPI) and Assertio Holdings (ASRT) Investor Alert: 6-DAY DEADLINE in Securities Lawsuit – Hagens BermanSeptember 19, 2025 | globenewswire.comDEADLINE NEXT WEEK: Berger Montague Advises Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) Investors to Contact the Firm Before September 24, 2025September 18, 2025 | globenewswire.comROSEN, TRUSTED INVESTOR COUNSEL, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure ...September 16, 2025 | bakersfield.comBROSEN, TRUSTED INVESTOR COUNSEL, Encourages Spectrum Pharmaceuticals, Inc. Investors to Secure Counsel Before Important September 24 Deadline in Securities Class Action – SPPISeptember 16, 2025 | globenewswire.comSPECTRUM ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Spectrum Pharmaceuticals, Inc. and Encourages Investors to Contact the FirmSeptember 15, 2025 | globenewswire.comSpectrum Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPPISeptember 15, 2025 | prnewswire.comSPPI Investors Have Opportunity to Lead Spectrum Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law FirmSeptember 15, 2025 | prnewswire.comDEADLINE APPROACHING: Berger Montague Advises Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) Investors to Inquire About a Securities Fraud Class Action by September 24, 2025September 12, 2025 | prnewswire.comSPPI Investors Have Opportunity to Lead Spectrum Pharmaceuticals, Inc. Securities Fraud LawsuitSeptember 10, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSPPI, LXRX, NERV, ALBO, and EOLS Company DescriptionsAlbireo Pharma NASDAQ:ALBOAlbireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA.Evolus NASDAQ:EOLS$6.74 -0.09 (-1.25%) As of 01:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.Lexicon Pharmaceuticals NASDAQ:LXRX$1.42 +0.03 (+1.80%) As of 01:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.Minerva Neurosciences NASDAQ:NERV$4.96 -0.43 (-7.90%) As of 01:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.Spectrum Pharmaceuticals NASDAQ:SPPISpectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Is Oracle’s AI Rally Over? Wall Street Thinks ORCL Could Hit $400 3 Pharmaceutical Growth Stocks to Buy and Hold for 10 Years Why Micron Stock Could Soar 35% on AI Memory Demand WesBanco Insiders Signal Confidence With Coordinated Buys The Best AI for Picking Stocks, Ranked by Performance Will D-Wave's European Expansion Keep Fueling the Rally? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
